Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
Information source: NovaCardia
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heart Failure, Congestive; Renal Insufficiency
Intervention: KW-3902IV (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: NovaCardia
Summary
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and
measure its effect on renal function.
Clinical Details
Official title: Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety Study
Primary outcome: Comparison of KW-3902IV alone or with loop diuretic on renal function.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Stable congestive heart failure
- Impaired renal function
- Taking oral loop diuretic
Exclusion Criteria:
- Acutely decompensated (unstable) and end stage heart failure
- Diuretics other than loop diuretics
- Pregnant or nursing
- Inability to follow instructions
- Participation in another clinical trial within past 30 days
Locations and Contacts
san diego, California, United States
baltimore, Maryland, United States
boston, Massachusetts, United States
ayer, Massachusetts, United States
kalamazoo, Michigan, United States
tullahoma, Tennessee, United States
Additional Information
Starting date: September 2005
Last updated: January 28, 2008
|
